BIOCRATES Life Sciences AG – AAIC Researchers Report New Data on How Gut Bacteria and Lipid Metabolism May Influence Alzheimer’s and Other Brain Diseases
The issuer is solely responsible for the content of this announcement.
BIOCRATES Life Sciences AG – AAIC Researchers Report New Data on How Gut Bacteria and Lipid Metabolism May Influence Alzheimer’s and Other Brain Diseases
BIOCRATES’ Technology Enables Research of Host Microbiome Interactions to Investigate Neurodegenerative Diseases
Innsbruck, Austria – July 25th, 2018 – BIOCRATES Life Sciences AG, a global leader in targeted metabolomics, reported today the Alzheimer’s Disease Metabolomics Consortium’s (ADMC) new breakthrough in Alzheimer’s research, which connects the Gut-Liver-Brain axis in the development and progression of Alzheimer’s disease (AD). During the Alzheimer’s Association International Conference (AAIC), Chicago, USA, researchers reported new data on how gut bacteria and lipid metabolism may influence AD.
Alzheimer’s disease is a devastating and progressive neurological disorder that affects more than 60 million people worldwide. Despite major effort by researchers, the pathophysiology of this disease is not yet fully understood. However, this week in Chicago at the AAIC, scientists showed that changes in intestinal bacterial populations or activity is associated with cognitive and brain imaging changes and atrophy in Alzheimer’s disease and that this might apply to other neuropsychiatric diseases.
Utilizing technology developed by BIOCRATES, which enables readouts of the host microbiome interaction, scientists shared their breakthrough findings that liver gut metabolic defects are correlated with cognitive decline in AD. Furthermore, these findings show that liver gut metabolic defects have an influence on the pathological features of AD, including neuroinflammation and amyloid-beta deposition.
